insights_auto
Pse është rritur GIS 3,58%?
Zhytu më thellëchevron_right
GIS:FRA
Gilead Sciences, Inc
135,56 €
arrow_upward
+3,58%(+4,68) 1D
12 tet, 3:56:42 m.d., GMT+2 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për GIS...
Hap
134,80 €
I lartë
135,56 €
I ulët
134,80 €
Kapitalizimi i tregut
186,24Â mld
Vëllimi mesatar
386,00
Vëllimi
1,16 mijë
Maksimumi 52-javor
135,56 €
Minimumi 52-javor
97,79 €
Numri i punonjësve
17 mijë
Hap
134,80 €
I lartë
135,56 €
I ulët
134,80 €
Kapitalizimi i tregut
186,24Â mld
Vëllimi mesatar
386,00
Vëllimi
1,16 mijë
Maksimumi 52-javor
135,56 €
Minimumi 52-javor
97,79 €
Numri i punonjësve
17 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Yahoo Finance
·
1 orë më parë
Gilead Sciences' Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
ad-hoc-news.de
·
3 orë më parë
Gilead Sciences stock trades at EUR 135.59, volume 17.2 percent above average
Insider Monkey
·
3 orë më parë
Can Gilead (GILD) Stock Continue Rising in 2027?
Investing.com
·
5 orë më parë
BofA raises Gilead Sciences stock price target on growth outlook
Profili
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Rreth Gilead Sciences, Inc
Drejtori ekzekutivDaniel O'Day
Punonjësit17 mijë
Themeluar më22 qer 1987
SeliaFoster City, Kalifornia, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtigilead.com